logo
AI Icon𝛼SK or Search
ENTITY
HUTCHMED

HUTCHMED (HCM US)

56
Analysis
Health Care • Hong Kong
HUTCHMED is an innovative, commercial-stage biopharmaceutical company focused on discovering, developing, manufacturing, and commercializing targeted therapies and immunotherapies for cancer and immunological diseases. The company has several novel oncology products marketed in China, with one also approved in the US, Europe, and Japan. HUTCHMED was founded in 2000 and is headquartered in Hong Kong.
more
bullish•HUTCHMED
•10 Aug 2020 19:08•Issuer-paid

Hutchison China MediTech - To China and beyond

Hutchison China MediTech (HCM) continues to move swiftly towards its goal of globalization of its innovative oncology assets and building a fully...

Logo
Share
bullish•HUTCHMED
•07 Aug 2020 16:16•Issuer-paid

Hutchison China MediTech - To China and beyond

Hutchison China MediTech (HCM) continues to move swiftly towards its goal of globalisation of its innovative oncology assets and building a fully...

Logo
Share
bullish•HUTCHMED
•06 Jul 2020 23:48•Issuer-paid

Hutchison China MediTech - Eye of the tiger

Hutchison China MediTech (HCM) is on the brink of global launches of two assets from its internally developed oncology portfolio. In 2022 we expect...

Logo
Share
bullish•HUTCHMED
•06 Jul 2020 21:34•Issuer-paid

Hutchison China MediTech - Eye of the tiger

Hutchison China MediTech (HCM) is on the brink of global launches of two assets from its internally developed oncology portfolio. In 2022 we expect...

Logo
Share
bullish•HUTCHMED
•22 Apr 2020 19:00•Issuer-paid

Hutchison China MediTech - Fortune favours the brave

Notwithstanding the COVID-19 pandemic challenges, Hutchison China MediTech (HCM) remains on track for potential approval and launches of two...

Logo
Share

Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.70.4

x